Publications / Posters :: ContraFect Corporation (CFRX)

Publications / Posters

Technology

Home
Technology
Publications / Posters

Publications

The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis

Antimicrobial Agents & Chemotherapy, (2019) 63 (4) e02291-18

Bacteriophage Lysin CF-301: a Potent Anti-Staphylococcal Biofilm Agent

Antimicrob. Agents Chemother (2017) 61 (7) e02666-16

Combination Therapy with Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia

Journal of Infectious Diseases, (2014) 209 (9): 1469-1478.

Posters

Lysin GN123 Resensitizes Cabapenem-Resistant Pseudomonas aeruginosa to Imipenem

Lysin GN123 Resensitizes Cabapenem-Resistant Pseudomonas aeruginosa to Imipenem

Presented at ECCMID 2019, April 13, 2019

Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid against biofilm-forming Staph epidermidis isolates

Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid against biofilm-forming Staph epidermidis isolates

Presented at ECCMID 2019, April 13, 2019

Comparison of Lysin CF-301 (exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates

Comparison of Lysin CF-301 (exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates

Presented at ID Week 2018, October 5, 2018

CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins

CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins

Presented at ASM-ESCMID 2018, September 4, 2018

Bacteriophage Lysins Can Be Engineered to Exert a Rapid and Potent Bactericidal Effect against Pseudomonas aeruginosa in Serum

Bacteriophage Lysins Can Be Engineered to Exert a Rapid and Potent Bactericidal Effect against Pseudomonas aeruginosa in Serum

Presented at ASM 2018, June 10, 2018

Lysin CF-301 Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis

Lysin CF-301 Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis

Presented at ASM 2018, June 10, 2018

Lysin CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the Emergence of Reduced Susceptibilities to VAN Within Cardiac Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE)

Lysin CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the Emergence of Reduced Susceptibilities to VAN Within Cardiac Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE)

Presented at ASM 2018, June 10, 2018

Lysin CF-301 Demonstrates Potent in Vitro Activity against a Range of Staphylococcus and Streptococcus Species Associated with Complicated Bacteremia and Infective Endocarditis in Humans

Lysin CF-301 Demonstrates Potent in Vitro Activity against a Range of Staphylococcus and Streptococcus Species Associated with Complicated Bacteremia and Infective Endocarditis in Humans

Presented at ASM 2018, June 10, 2018

CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals

CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals

Presented at ASM 2018, June 10, 2018

Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of Staph aureus infective endocarditis

Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of Staph aureus infective endocarditis

Presented at 28th ECCMID, April 24, 2018

1
2
3
4
Next »